Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study will evaluate the efficacy and safety of low doses of SPN-812 in adolescents 12-17 years of age.
Epistemonikos ID: e6f05c5e6e03a762d4bca4489f6cb5ffaa76bb7b
First added on: May 21, 2024